Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Oct 11, 2017 at 10:55 AM EDT

Short Sellers Run for Cover From Major Pharma

The September 29 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Oct 10, 2017 at 10:55 AM EDT

Why AnaptysBio Is One of Tuesday’s Top Stocks

AnaptysBio is easily one of the best performing stocks on Tuesday, with its shares jumping over 70% in this session.

Chris Lange | Oct 10, 2017 at 9:00 AM EDT

KalVista Pharma Wins Big on Merck Collaboration

KalVista Pharmaceuticals saw its shares absolutely explode early on Tuesday after it was announced that the firm would be collaborating…

Chris Lange | Oct 7, 2017 at 8:10 AM EDT

Even More Biopharma and FDA Catalysts Coming in October

24/7 Wall St. has collected a few more catalysts that are coming up in October for biotech and pharmaceutical companies.

Lee Jackson | Oct 6, 2017 at 10:25 AM EDT

4 Biotech Stocks to Buy That May See Huge Volatility From Earnings

Some of the top biotech stocks could become extremely volatile before and after earnings. These four that may be worth…

Chris Lange | Oct 5, 2017 at 9:55 AM EDT

Why ImmunoGen’s Secondary Makes Sense

ImmunoGen saw its shares make a sharp turn downward on Thursday morning after the stock has seen an incredible year…

John Harrington | Oct 5, 2017 at 8:05 AM EDT

Why Exercise, Any Exercise, Is Beneficial to the Brain

Relatively modest changes in levels of exercise may have important public mental health benefits and prevent a substantial number of…

Chris Lange | Oct 4, 2017 at 1:30 PM EDT

What CytomX Gets From Its Huge Amgen Collaboration

CytomX Therapeutics shares made a solid gain in Wednesday’s session following announcement of a strategic collaboration with Amgen in immuno-oncology.

Chris Lange | Oct 4, 2017 at 10:56 AM EDT

Amicus Therapeutics Wins Big at World Muscle Society Conference

Amicus Therapeutics is another biotech player seeing a nice boost from the World Muscle Society Conference in France.

Chris Lange | Oct 4, 2017 at 10:10 AM EDT

Why Catabasis Shares Are Surging

Catabasis Pharmaceuticals shares continued their incredible climb after the announcement of positive efficacy results from its MoveDMD trial in a…

Chris Lange | Oct 4, 2017 at 8:55 AM EDT

Is This the Turnaround That Mylan Has Waited For?

Finally some good news out of Mylan, which potentially is bringing the shares back to about even for 2017.

Jon C. Ogg | Oct 3, 2017 at 10:55 AM EDT

Credit Suisse Identifies Top Mid-Large Cap Biotech and Pharma Stocks for Big Upside

U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. But this part of…

Chris Lange | Oct 2, 2017 at 1:40 PM EDT

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade…

Chris Lange | Oct 2, 2017 at 12:25 PM EDT

Why Endocyte Is Monday’s Biggest Winner

Endocyte kicked off the week with an incredible gain, making it one of the best, if not the best, performing…

Chris Lange | Oct 2, 2017 at 10:40 AM EDT

FDA Update Keeps Rigel Pharmaceuticals Above Water

Rigel Pharmaceuticals has suffered over the past year, but it seems this update may be the catalyst it has been…

1 … 153 154 155 156 157 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Run for Cover From Major Pharma

Why AnaptysBio Is One of Tuesday’s Top Stocks

KalVista Pharma Wins Big on Merck Collaboration

Even More Biopharma and FDA Catalysts Coming in October

4 Biotech Stocks to Buy That May See Huge Volatility From Earnings

Why ImmunoGen’s Secondary Makes Sense

Why Exercise, Any Exercise, Is Beneficial to the Brain

What CytomX Gets From Its Huge Amgen Collaboration

Amicus Therapeutics Wins Big at World Muscle Society Conference

Why Catabasis Shares Are Surging

Is This the Turnaround That Mylan Has Waited For?

Credit Suisse Identifies Top Mid-Large Cap Biotech and Pharma Stocks for Big Upside

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Why Endocyte Is Monday’s Biggest Winner

FDA Update Keeps Rigel Pharmaceuticals Above Water

“Grow a Spine”: All-In Podcast Pushes Back on AI Regulation and Calls PayPal’s $60 Takeover Offer Just an Opening Bid

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

$3,000 a Month in Sun City: Here’s How to Retire There at 62 Without Touching Your Savings

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

$3,000 a Month in Sun City: Here's How to Retire There at 62 Without Touching Your Savings

“Grow a Spine”: All-In Podcast Pushes Back on AI Regulation and Calls PayPal’s $60 Takeover Offer Just an Opening Bid

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Run for Cover From Major Pharma

Why AnaptysBio Is One of Tuesday’s Top Stocks

KalVista Pharma Wins Big on Merck Collaboration

Even More Biopharma and FDA Catalysts Coming in October

4 Biotech Stocks to Buy That May See Huge Volatility From Earnings

Why ImmunoGen’s Secondary Makes Sense

Why Exercise, Any Exercise, Is Beneficial to the Brain

What CytomX Gets From Its Huge Amgen Collaboration

Amicus Therapeutics Wins Big at World Muscle Society Conference

Why Catabasis Shares Are Surging

Is This the Turnaround That Mylan Has Waited For?

Credit Suisse Identifies Top Mid-Large Cap Biotech and Pharma Stocks for Big Upside

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Why Endocyte Is Monday’s Biggest Winner

FDA Update Keeps Rigel Pharmaceuticals Above Water

“Grow a Spine”: All-In Podcast Pushes Back on AI Regulation and Calls PayPal’s $60 Takeover Offer Just an Opening Bid

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

$3,000 a Month in Sun City: Here’s How to Retire There at 62 Without Touching Your Savings

Featured Reads

The $1.2 Million 401(k) Tax Trap That Costs Retirees 40% in Hidden Surcharges

$3,000 a Month in Sun City: Here's How to Retire There at 62 Without Touching Your Savings